230 related articles for article (PubMed ID: 31060205)
1. Immune System Stimulation by Oncolytic Rodent Protoparvoviruses.
Angelova A; Rommelaere J
Viruses; 2019 May; 11(5):. PubMed ID: 31060205
[TBL] [Abstract][Full Text] [Related]
2. A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies.
Hartley A; Kavishwar G; Salvato I; Marchini A
Annu Rev Virol; 2020 Sep; 7(1):537-557. PubMed ID: 32600158
[TBL] [Abstract][Full Text] [Related]
3. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic parvoviruses as cancer therapeutics.
Rommelaere J; Geletneky K; Angelova AL; Daeffler L; Dinsart C; Kiprianova I; Schlehofer JR; Raykov Z
Cytokine Growth Factor Rev; 2010; 21(2-3):185-95. PubMed ID: 20211577
[TBL] [Abstract][Full Text] [Related]
5. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
Bretscher C; Marchini A
Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic parvoviruses: from basic virology to clinical applications.
Marchini A; Bonifati S; Scott EM; Angelova AL; Rommelaere J
Virol J; 2015 Jan; 12():6. PubMed ID: 25630937
[TBL] [Abstract][Full Text] [Related]
7. Double-faceted mechanism of parvoviral oncosuppression.
Geletneky K; Nüesch JP; Angelova A; Kiprianova I; Rommelaere J
Curr Opin Virol; 2015 Aug; 13():17-24. PubMed ID: 25841215
[TBL] [Abstract][Full Text] [Related]
8. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.
Allaume X; El-Andaloussi N; Leuchs B; Bonifati S; Kulkarni A; Marttila T; Kaufmann JK; Nettelbeck DM; Kleinschmidt J; Rommelaere J; Marchini A
J Virol; 2012 Apr; 86(7):3452-65. PubMed ID: 22258256
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
[TBL] [Abstract][Full Text] [Related]
10. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
[TBL] [Abstract][Full Text] [Related]
11. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.
Raykov Z; Grekova S; Galabov AS; Balboni G; Koch U; Aprahamian M; Rommelaere J
Oncol Rep; 2007 Jun; 17(6):1493-9. PubMed ID: 17487410
[TBL] [Abstract][Full Text] [Related]
12. Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses.
Angarita FA; Acuna SA; Ottolino-Perry K; Zerhouni S; McCart JA
Trends Mol Med; 2013 Jun; 19(6):378-92. PubMed ID: 23540715
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
[TBL] [Abstract][Full Text] [Related]
14. To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses.
Cassady KA; Haworth KB; Jackson J; Markert JM; Cripe TP
Viruses; 2016 Feb; 8(2):. PubMed ID: 26861381
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic virotherapy as immunotherapy.
Melcher A; Harrington K; Vile R
Science; 2021 Dec; 374(6573):1325-1326. PubMed ID: 34882456
[TBL] [Abstract][Full Text] [Related]
16. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.
Sieben M; Schäfer P; Dinsart C; Galle PR; Moehler M
Int J Cancer; 2013 Jun; 132(11):2548-56. PubMed ID: 23151948
[TBL] [Abstract][Full Text] [Related]
17. From virotherapy to oncolytic immunotherapy: where are we now?
Coffin RS
Curr Opin Virol; 2015 Aug; 13():93-100. PubMed ID: 26121656
[TBL] [Abstract][Full Text] [Related]
18. Virotherapy--cancer targeted pharmacology.
Tedcastle A; Cawood R; Di Y; Fisher KD; Seymour LW
Drug Discov Today; 2012 Mar; 17(5-6):215-20. PubMed ID: 22198165
[TBL] [Abstract][Full Text] [Related]
19. Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection.
Alvarez-Breckenridge CA; Choi BD; Suryadevara CM; Chiocca EA
Curr Opin Virol; 2015 Aug; 13():25-32. PubMed ID: 25846988
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Rodent Protoparvoviruses Evade a TLR- and RLR-Independent Antiviral Response in Transformed Cells.
Angelova A; Pierrard K; Detje CN; Santiago E; Grewenig A; Nüesch JPF; Kalinke U; Ungerechts G; Rommelaere J; Daeffler L
Pathogens; 2023 Apr; 12(4):. PubMed ID: 37111493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
